pfizer glp-1 news The Pricing Shift! Lilly Wins, Novo Falls, Struggles: GLP-1 GAME-CHANGING': Pfizer CEO touts new
Description
10.1093/ntr/ntab066 63 YangY.HeL.HanS.YangN.LiuY.WangX.et al (2025)
Other patients may be unable to tolerate the side effects of the standard starter dose, but microdosing allows them to begin at an even lower level
Option 3: Switching to Tirzepatide Another option for patients who are not achieving their weight loss goals on certain GLP-1s, like Semaglutide, is switching to Tirzepatide, a newer dual-action GLP-1 and GIP receptor agonist that has shown more impressive weight loss results in recent clinical trials
doi: 10.1159/000357810 61 GreenmanYTordjmanKSternN
Her improvement with a GLP-1 agonist was attributed to anti-inflammatory effects, such as the reduction of IL-17 and IL-6 levels
Glickman explains
